NO20041494L - Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form - Google Patents

Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form

Info

Publication number
NO20041494L
NO20041494L NO20041494A NO20041494A NO20041494L NO 20041494 L NO20041494 L NO 20041494L NO 20041494 A NO20041494 A NO 20041494A NO 20041494 A NO20041494 A NO 20041494A NO 20041494 L NO20041494 L NO 20041494L
Authority
NO
Norway
Prior art keywords
sites
insulin
hisb
insulin hexamer
novel ligands
Prior art date
Application number
NO20041494A
Other languages
English (en)
Inventor
Palle Jakobsen
Niels Christian Kaarsholm
Peter Madsen
Helle Birk Olsen
Soren Ostergaard
Svend Ludvigsen
Anders Klarskov Petersen
Dorte Bjerre Steensgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20041494L publication Critical patent/NO20041494L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20041494A 2001-09-14 2004-04-13 Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form NO20041494L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101337 2001-09-14
US32392501P 2001-09-21 2001-09-21
DKPA200201066 2002-07-05
US39605102P 2002-07-10 2002-07-10
PCT/DK2002/000595 WO2003027081A2 (en) 2001-09-14 2002-09-13 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER

Publications (1)

Publication Number Publication Date
NO20041494L true NO20041494L (no) 2004-04-13

Family

ID=27439845

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041494A NO20041494L (no) 2001-09-14 2004-04-13 Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form

Country Status (15)

Country Link
US (1) US7879893B2 (no)
EP (1) EP1429763B1 (no)
JP (1) JP4554207B2 (no)
CN (1) CN1558762A (no)
AT (1) ATE363278T1 (no)
BR (1) BR0212522A (no)
CA (1) CA2460541A1 (no)
CZ (1) CZ2004313A3 (no)
DE (1) DE60220424T2 (no)
ES (1) ES2288195T3 (no)
HU (1) HUP0401492A3 (no)
MX (1) MXPA04002404A (no)
NO (1) NO20041494L (no)
PL (1) PL369119A1 (no)
WO (1) WO2003027081A2 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US20040063098A1 (en) * 2002-09-26 2004-04-01 Hargreaves John S. Methods for producing multilayer ligand arrays
WO2004043955A1 (en) * 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
ATE378063T1 (de) * 2002-12-20 2007-11-15 Novo Nordisk As Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7781464B2 (en) 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
BRPI0408229A (pt) * 2003-03-11 2006-02-21 Novo Nordisk As preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
CA2531170C (en) * 2003-07-02 2011-05-10 Teva Gyogyszergyar Reszvenytarsasag Aztreonam l-lysine and methods for the preparation thereof
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
US7037927B2 (en) * 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005054291A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
EP1757591A4 (en) 2004-05-26 2010-05-05 Eisai R&D Man Co Ltd ZIMTSÄUREAMIDVERBINDUNG
KR20070029247A (ko) 2004-07-08 2007-03-13 노보 노르디스크 에이/에스 폴리펩티드 연장 태그
EP1768694A1 (en) * 2004-07-09 2007-04-04 Novo Nordisk A/S Phamaceutical preparations comprising insulin
BRPI0514133A (pt) * 2004-08-05 2008-05-27 Hoffmann La Roche compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
WO2006029634A2 (en) * 2004-09-17 2006-03-23 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
RU2430920C2 (ru) * 2004-09-28 2011-10-10 Оцука Фармасьютикал Ко., Лтд. Карбостирильное соединение
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
TW200800978A (en) * 2006-03-23 2008-01-01 Otsuka Pharma Co Ltd Carbazole compound
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US9169219B2 (en) 2012-02-21 2015-10-27 Bayer Intellectual Property Gmbh Herbicidally active 4-nitro-substituted N-(tetrazol-5-yl)-, N-(triazol-5-yl)-, and N-(1,3,4-0XADIAZOL-2-yl)aryl carboxylic acid amides
EP2844260A4 (en) * 2012-04-30 2016-06-29 Anderson Gaweco ROR MODULATORS AND ITS USES
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
JP6156845B2 (ja) * 2014-03-04 2017-07-05 株式会社島津製作所 マトリックス支援レーザ脱離イオン化質量分析用マトリックス
CA2968884A1 (en) * 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
EP3229807A4 (en) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibitors of cellular necrosis and related methods
EP3282846A4 (en) * 2015-03-23 2018-09-26 University of Miami Inhibitors of the notch transcriptional activation complex and methods for use of the same
CA3012846A1 (en) 2016-02-16 2017-08-24 Massachusetts Institute Of Technology Max binders as myc modulators and uses thereof
US11325901B2 (en) * 2016-06-28 2022-05-10 University Of Kentucky Research Foundation Prostaglandin E synthase inhibitors and methods for utilizing the same
EP3558992A4 (en) * 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. ACTIVATOR OF TREK (TWIK-ASSOCIATED K + CHANNELS) CHANNELS
CN112351975A (zh) * 2018-03-16 2021-02-09 俄克拉何马大学董事会 过氧化物酶体增殖物活化受体α的激动剂和使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP1982004086A (es) 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
DE69914934T2 (de) * 1998-11-18 2005-01-05 Novo Nordisk A/S Stabile, wässrige insulin-präparate ohne phenol und cresol

Also Published As

Publication number Publication date
ES2288195T3 (es) 2008-01-01
US20030229120A1 (en) 2003-12-11
EP1429763A2 (en) 2004-06-23
PL369119A1 (en) 2005-04-18
WO2003027081A2 (en) 2003-04-03
ATE363278T1 (de) 2007-06-15
HUP0401492A2 (hu) 2004-11-29
WO2003027081A3 (en) 2004-03-25
CN1558762A (zh) 2004-12-29
DE60220424T2 (de) 2008-03-06
HUP0401492A3 (en) 2008-05-28
CA2460541A1 (en) 2003-04-03
CZ2004313A3 (cs) 2004-07-14
EP1429763B1 (en) 2007-05-30
US7879893B2 (en) 2011-02-01
JP2005508335A (ja) 2005-03-31
DE60220424D1 (de) 2007-07-12
BR0212522A (pt) 2004-08-10
JP4554207B2 (ja) 2010-09-29
MXPA04002404A (es) 2004-05-31

Similar Documents

Publication Publication Date Title
NO20041494L (no) Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form
DE60237828D1 (de) Neue verbindungen
UA84432C2 (ru) Очищенные пептиды и соединения, которые их содержат
PT1086124E (pt) Ciclosporinas novas
GB2431404A (en) Peptide
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
GB0004128D0 (en) Novel compounds
DE69326250D1 (de) Neuropeptide y antagoniste
SE0101038D0 (sv) Novel compounds
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE60231825D1 (de) Behandlung von infektionen verursacht von mikroorganismen
AU2003291972A8 (en) Pharmaceutical compositions comprising insulin and legends of insulin hexamer
DK1127064T3 (da) Hidtil ukendte aminosyresekvenser, DNA, der koder for aminosyresekvenserme, antistoffer, der er rettet mod sådanne sekvenser, og forskellige anvendelser deraf
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler
EA200200807A1 (ru) Аминокислотные соединения и их применение в качестве ингибиторов nep, ace и ece
HRP20020703B1 (en) Memno peptides, a process for their preparation and their use
CY1105363T1 (el) Ν,ν΄-διυποκατεστημενες ενωσεις πιπepαζινης και η χρηση τους σαν αναλγητικα μεσα
HUP0303174A2 (hu) A terbinafin almasav addíciós sói, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL159493A0 (en) Pharmaceutical formulation containing an ltb4 antagonist
DE60002694D1 (de) Verwendung von copolymeren abgeleitet von polyamiden als geliermittel für wenig polare verbindungen
WO2003089472A3 (en) Anti-nls scfv and peptides and uses thereof in nuclear import inhibition
WO2003029290A1 (fr) Transporteur de medicament et son utilisation
Kim et al. Nucleoplasmic Terminal Protein-like p87
BR0215037A (pt) Composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application